Detalhe da pesquisa
1.
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
Cell
; 164(3): 392-405, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26806128
2.
Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.
Cell
; 167(3): 684-694.e9, 2016 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27768891
3.
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
JAMA
; 323(14): 1369-1377, 2020 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286643
4.
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Science
; 373(6561): 1372-1377, 2021 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34385356
5.
Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
PLoS One
; 13(12): e0209437, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30566528
6.
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Nat Microbiol
; 3(6): 670-677, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29736037
7.
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance.
JCI Insight
; 2(9)2017 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28469084
8.
Recognition of influenza H3N2 variant virus by human neutralizing antibodies.
JCI Insight
; 1(10)2016 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27482543
9.
H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.
J Clin Invest
; 126(4): 1482-94, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26950424